ArticleGastroenterology2021
A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer.
Article in Gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Predicting Recurrence After Curative-Intent Resection of T1 Colorectal Cancer With Transcriptomics
Biobank for Validating Liquid Biopsy in Predicting the Prognosis of Superficial Colonic Lesions
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- Risk of lymph-node metastasis in early onset T1 colorectal cancer: a systematic review and meta-analysis.Journal of gastroenterology · 2026Pooled it
- Prior endoscopic resection does not affect the outcome of secondary surgery for T1 colorectal cancer, a systematic review and meta-analysis.International journal of colorectal disease · 2022Pooled it
- External validation and comparison of five prediction models for lymph node metastasis after noncurative endoscopic submucosal dissection for early gastric cancer.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- T1 colorectal cancer: determinants of lymph node metastasis, survival patterns, and risk-adapted management.Updates in surgery · 2026Review
- Tumour location and mismatch repair status impact gene expression profiles associated with lymph node metastases in T1 colon cancers.Scientific reports · 2026Article
- Circulating tumor DNA methylation-based method for noninvasive detection and stage stratification of colorectal tumor.Clinical epigenetics · 2026Article
- An exosome-based liquid biopsy to predict molecular residual disease for the identification of high-risk patients with stage II-III colorectal cancer: the CLEAR study.Molecular cancer · 2026Observational
- miR-195 and miR-549a Are Essential Biomarkers for Early-Onset Colorectal Cancer.International journal of molecular sciences · 2026Article
- A machine learning-based transcriptomic signature for predicting tumor recurrence after curative resection in T1 colorectal cancer: a retrospective multicenter cohort study (The Tw1CE trial).International journal of surgery (London, England) · 2026Article
- A Liquid Biopsy Assay of Exosomal miRNA for Non-invasive Identification of Lymph Node Metastasis in Early Gastric Cancer.Annals of surgical oncology · 2025Article
- A promising frontier of circulating messenger RNA in liquid biopsy: From mechanisms to clinical applications.International journal of cancer · 2025Review
- Polymeric immunoglobulin receptor (pIgR) in cancer progression: a critical role and potential therapeutic target.Apoptosis : an international journal on programmed cell death · 2025Review
- Surveillance and Surgical Salvage Treatment for Endoscopically Removed T1 Colorectal Cancers.Gut and liver · 2025Review
- Comparative microRNA signatures based on liquid biopsy to identify lymph node metastasis in T1 colorectal cancer patients undergoing upfront surgery or endoscopic resection.Cell death discovery · 2025Article
- Somatic mutation correlation with lymph node metastasis and prognosis in T1/2 stage colorectal cancer patients: A propensity score matching analysis.Clinical and translational medicine · 2025Article
- Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring.Molecular cancer · 2024Review
- Article
- How secure can we expect the surveillance policies to be after the implementation in T1 polyps with carcinoma?World journal of gastrointestinal endoscopy · 2024Article
- Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy.Journal for immunotherapy of cancer · 2024Review
- Comparative prediction of lymph node metastasis in pT1 colorectal cancer among Western and Japanese guidelines.Frontiers in oncology · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
Abstract
BACKGROUND &
aimsWe recently reported use of tissue-based transcriptomic biomarkers (microRNA [miRNA] or messenger RNA [mRNA]) for identification of lymph node metastasis (LNM) in patients with invasive submucosal colorectal cancers (T1 CRC). In this study, we translated our tissue-based biomarkers into a blood-based liquid biopsy assay for noninvasive detection of LNM in patients with high-risk T1 CRC.
methodsWe analyzed 330 specimens from patients with high-risk T1 CRC, which included 188 serum samples from 2 clinical cohorts-a training cohort (N = 46) and a validation cohort (N = 142)-and matched formalin-fixed paraffin-embedded samples (N = 142). We performed quantitative reverse-transcription polymerase chain reaction, followed by logistic regression analysis, to develop an integrated transcriptomic panel and establish a risk-stratification model combined with clinical risk factors.
resultsWe used comprehensive expression profiling of a training cohort of LNM-positive and LMN-negative serum specimens to identify an optimized transcriptomic panel of 4 miRNAs (miR-181b, miR-193b, miR-195, and miR-411) and 5 mRNAs (AMT, forkhead box A1 [FOXA1], polymeric immunoglobulin receptor [PIGR], matrix metalloproteinase 1 [MMP1], and matrix metalloproteinase 9 [MMP9]), which robustly identified patients with LNM (area under the curve [AUC], 0.86; 95% confidence interval [CI], 0.72-0.94). We validated panel performance in an independent validation cohort (AUC, 0.82; 95% CI, 0.74-0.88). Our risk-stratification model was more accurate than the panel and an independent predictor for identification of LNM (AUC, 0.90; univariate: odds ratio [OR], 37.17; 95% CI, 4.48-308.35; P < .001; multivariate: OR, 17.28; 95% CI, 1.82-164.07; P = .013). The model limited potential overtreatment to only 18% of all patients, which is dramatically superior to pathologic features that are currently used (92%).
conclusionsA novel risk-stratification model for noninvasive identification of T1 CRC has the potential to avoid unnecessary operations for patients classified as high-risk by conventional risk-classification criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.